AOA Dx Analysis: $17M Raised
What is AOA Dx?
AOA Dx specializes in early cancer detection using AI-driven platforms, focusing on women's health through multi-omics technology and tumor marker gangliosides.
Employees
25
Founded
2020
Revenue
$5.7M
ZoomInfo
Product Features & Capabilities
- GlycoLocate™: multi-omics platform for early cancer detection, AKRIVIS GD™: blood test for early-stage ovarian cancer detection
How much AOA Dx raised
1 - $17 million
October 12, 2023Lead Investor: Good Growth Capital, RH, and others
Who are the founders of AOA Dx
OP
Oriana Papin-Zoghbi
CEO & Co-Founder
AF
Alex Fisher
COO & Co-Founder
AJ
Anna Jeter
Chief Business Officer & Co-Founder
Market Focus
AOA Dx primarily focuses on the healthcare industry, specifically in the area of early cancer detection through an AI-enabled platform that emphasizes women's health.
Competitors Overview
AOA Dx operates in the early cancer detection market, particularly focusing on women's health through AI-enabled platforms and multi-omics technology. Its main competitors include:
- Genecker: This company offers ultra-precision cancer diagnosis services using advanced technologies like CRISPR
Business Model
Revenue from proprietary technology commercialization and funding for cancer detection innovations.
Investors
- Avestria Ventures
- AlleyCorp
- The Helm
- RH Capital
See something that needs updating? Suggest edits to this profile.